PRLD
Prelude Therapeutics Inc
NASDAQ: PRLD · HEALTHCARE · BIOTECHNOLOGY
$5.23
+22.48% today
Updated 2026-04-30
Market cap
$275.98M
P/E ratio
—
P/S ratio
22.73x
EPS (TTM)
$-1.29
Dividend yield
—
52W range
$1 – $6
Volume
0.4M
Prelude Therapeutics Inc (PRLD) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $7.00M | $12.14M |
| Revenue growth (YoY) | — | — | — | — | — | — | — | +73.4% |
| Cost of revenue | $149000.00 | $382000.00 | $542000.00 | $2.24M | $3.04M | $1.17M | $1.77M | $1.71M |
| Gross profit | $-149000.00 | $-382000.00 | $-542000.00 | $-2.24M | $-3.04M | $-1.17M | $7.00M | $10.43M |
| Gross margin | — | — | — | — | — | — | 100.0% | 85.9% |
| R&D | $12.62M | $24.28M | $48.18M | $86.78M | $92.89M | $103.39M | $118.00M | $94.30M |
| SG&A | $2.35M | $3.83M | $10.59M | $26.96M | $30.65M | $28.88M | $28.72M | $22.41M |
| Operating income | $-14.97M | $-28.11M | $-58.76M | $-113.73M | $-123.54M | $-132.28M | $-139.71M | $-104.57M |
| Operating margin | — | — | — | — | — | — | -1995.9% | -861.3% |
| EBITDA | $-14.83M | $-27.73M | $-58.22M | $-112.82M | $-122.22M | $-131.11M | $-137.94M | $-102.86M |
| EBITDA margin | — | — | — | — | — | — | -1970.6% | -847.2% |
| EBIT | $-14.97M | $-28.11M | $-58.76M | $-113.73M | $-123.54M | $-132.28M | $-139.71M | $-104.57M |
| Interest expense | $0.00 | $0.00 | $0.00 | $2.04M | $1.32M | — | — | — |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-14.68M | $-27.57M | $-56.93M | $-110.78M | $-107.34M | $-121.83M | $-127.17M | $-99.50M |
| Net income growth (YoY) | — | -87.8% | -106.5% | -94.6% | +3.1% | -13.5% | -4.4% | +21.8% |
| Profit margin | — | — | — | — | — | — | -1816.8% | -819.6% |